We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-19.07%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$129M
AUM Growth
-$22M
Cap. Flow
-$11.1M
Cap. Flow %
-8.62%
Top 10 Hldgs %
47.53%
Holding
65
New
8
Increased
16
Reduced
26
Closed
13

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$3.31M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$2.19M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.82M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$994K
5
SDS icon
ProShares UltraShort S&P500
SDS
+$967K

Top Sells

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$10.7M
2
GILD icon
Gilead Sciences
GILD
+$2.74M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$1.5M
4
XNCR icon
Xencor
XNCR
+$1.32M
5
AMGN icon
Amgen
AMGN
+$1.28M

Sector Composition

Rank Sector Weight
1 Healthcare 73.12%
2 Miscellaneous 26.17%
3 Real Estate 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIOX
51
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$303K 0.23%
3,302
+945
+40% +$101K
GILD icon
52
Gilead Sciences
GILD
$185B
$301K 0.23%
3,282
-30,418
-90% -$2.74M
BCRX icon
53
BioCryst Pharmaceuticals
BCRX
$2.52B
– –
-100,000
Closed -$1.03M
ELDN icon
54
Eledon Pharmaceuticals
ELDN
$270M
– –
-383
Closed -$541K
IBB icon
55
iShares Biotechnology ETF
IBB
$10.8B
– –
-94,800
Closed -$10.7M
KALV
56
DELISTED
KalVista Pharmaceuticals
KALV
– –
-1,250
Closed -$63K
MGNX icon
57
MacroGenics
MGNX
$260M
– –
-30,000
Closed -$929K
NVAX icon
58
CALL
Novavax
NVAX
$1.49B
– –
-5,000
Closed -$839K
NVAX icon
59
PUT
Novavax
NVAX
$1.49B
– –
-5,000
Closed -$839K
XNCR icon
60
Xencor
XNCR
$2.15B
– –
-90,000
Closed -$1.32M
NSTG
61
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-102,200
Closed -$1.5M
INFI
62
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-30,000
Closed -$236K
PLXP
63
DELISTED
PLx Pharma Inc. Common Stock
PLXP
– –
-3,125
Closed -$280K
SRRA
64
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-750
Closed -$451K
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q1 2016 Portfolio in Review

As of Q1 2016, Opus Point Partners Management held 65 positions worth $129M, down 15% from $151M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Opus Point Partners Management withdrew a net $11.1M in Q1 2016, closing 13 positions and reducing 26 holdings. Its most notable exit was iShares Biotechnology ETF, an estimated $10.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in Pfizer worth $3.26M.

  • Opus Point Partners Management's largest Q1 2016 buy was Pfizer: 115,940 shares worth $3.26M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q1 2016, an estimated $2.19M increase.
  • Opus Point Partners Management's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $2.74M.
  • Opus Point Partners Management fully exited iShares Biotechnology ETF in Q1 2016, selling an estimated $10.7M.
  • Opus Point Partners Management's ten largest holdings make up 48% of its $129M portfolio in Q1 2016.
  • Opus Point Partners Management opened 8 new positions and closed 13 in Q1 2016.
  • Opus Point Partners Management's portfolio value fell 15% quarter-over-quarter to $129M.

Based on Opus Point Partners Management's 13F filing for Q1 2016, filed 13 May 2016.